Evidence map›Paper›PMID 31792807›Full record

ReviewReviews in endocrine & metabolic disorders2020

Endocrine disrupting chemicals: exposure, effects on human health, mechanism of action, models for testing and strategies for prevention.

Bayram Yilmaz, Hakan Terekeci, Suleyman Sandal, Fahrettin Kelestimur

2 registry-linked trialsAbstract readReview
PubMed Publisher
In one paragraph

Review in Reviews in endocrine & metabolic disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 254 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
254citing papers in PubMed, 8 pooled it
21.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06968455 completednot on this mapstarted 2023, after this paper: background citation

The Association of Endocrine Disruptors and Toxic and Essential Chemical Elements With Polycystic Ovary Syndrome

TypeobservationalSponsorUniversity Medical Centre LjubljanaRan2023 to 2024Enrolled70ConditionsPolycystic Ovary SyndromeArmsparabens
NCT07560579 naactive not recruitingnot on this mapstarted 2025, after this paper: background citation

Weight Loss and Endocrine Disrupting Chemicals (EDCs): Lifestyle Interventions to Lose Weight and Reduce EDC Exposure in Individuals With Overweight/Obesity

TypeinterventionalSponsorMillion Marker Wellness, Inc.Ran2025 to 2026Enrolled226ConditionsObesity &Amp, Amp, Amp, OverweightArmsEducational curriculum, Weight loss Application, Urinary EDC metabolite testing, Siphox clinic biomarker test, Weight loss reporting
3 · Its place in the literature

Who cites it

254 citing papers in PubMed, 8 syntheses or guidelines pooled it, 692 citations in OpenAlex.

  1. A Review of Biomonitoring for Atrazine and Atrazine Metabolites Using Blood, Urine, and Sweat-Based Assays.International journal of environmental research and public health · 2026
    Pooled it
  2. Association between exposure to endocrine-disrupting chemicals and polycystic ovary syndrome: a systematic review.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2026
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Emerging roles of mJournal of assisted reproduction and genetics · 2026
    Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

194 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Bayram YilmazDepartment of Physiology, Faculty of Medicine, Yeditepe University, Istanbul, Turkey.
Hakan TerekeciDepartment of Internal Medicine, Faculty of Medicine, Yeditepe University, Istanbul, Turkey.
Suleyman SandalDepartment of Physiology, Faculty of Medicine, Inonu University, Malatya, Turkey.
Fahrettin KelestimurDepartment of Endocrinology, Faculty of Medicine, Yeditepe University, Istanbul, Turkey. fahrettin.kelestemur@yeditepe.edu.tr.
Yeditepe University · TRInonu University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endocrine Disrupting Chemicals (EDCs) are a global problem for environmental and human health. They are defined as "an exogenous chemical, or mixture of chemicals, that can interfere with any aspect of hormone action". It is estimated that there are about 1000 chemicals with endocrine-acting properties. EDCs comprise pesticides, fungicides, industrial chemicals, plasticizers, nonylphenols, metals, pharmaceutical agents and phytoestrogens. Human exposure to EDCs mainly occurs by ingestion and to some extent by inhalation and dermal uptake. Most EDCs are lipophilic and bioaccumulate in the adipose tissue, thus they have a very long half-life in the body. It is difficult to assess the full impact of human exposure to EDCs because adverse effects develop latently and manifest at later ages, and in some people do not present. Timing of exposure is of importance. Developing fetus and neonates are the most vulnerable to endocrine disruption. EDCs may interfere with synthesis, action and metabolism of sex steroid hormones that in turn cause developmental and fertility problems, infertility and hormone-sensitive cancers in women and men. Some EDCs exert obesogenic effects that result in disturbance in energy homeostasis. Interference with hypothalamo-pituitary-thyroid and adrenal axes has also been reported. In this review, potential EDCs, their effects and mechanisms of action, epidemiological studies to analyze their effects on human health, bio-detection and chemical identification methods, difficulties in extrapolating experimental findings and studying endocrine disruptors in humans and recommendations for endocrinologists, individuals and policy makers will be discussed in view of the relevant literature.

Indexed as

AnimalsEndocrine DisruptorsEnvironmental ExposureFemaleHumansMaleEndocrine DisruptorsEndocrine disruptorsEnvironmentEstrogenicExposureHuman healthPollutants

Identifiers

PMID31792807
OpenAlexW2992064964

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.